Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sutezolid - Global Alliance for TB Drug Development/Sequella

Drug Profile

Sutezolid - Global Alliance for TB Drug Development/Sequella

Alternative Names: PF-02341272; PF-2341272; PNU-100480; U 100480; U 101244; U 101603

Latest Information Update: 10 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator John Hopkins University; Pharmacia Corporation
  • Developer Global Alliance for TB Drug Development; Sequella
  • Class Acetamides; Amides; Antibacterials; Oxazolidinones; Small molecules; Thiamorpholines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 22 May 2019 Sequella plans the phase II SUDOCU trial for Tuberculosis (Newly diagnosed, Treatment-naive, Combination therapy) in South Africa and Tanzania in August 2019 (PO) (NCT03959566)
  • 28 Apr 2019 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in USA (PO, Suspension)
  • 29 Jun 2017 Global Alliance for TB Drug Development plans a phase I trial for Tuberculosis (In volunteers) in USA, in September 2017 (NCT03199313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top